文献速递精神分裂症与精神病性障碍

Claudin-5 剂量依赖性表达是精神分裂症的修饰因素

Dose-dependent expression of claudin-5 is a modifying factor in schizophrenia.
PubMed 文献 · Mol Psychiatry · 2017-10-10

精神分裂症影响高达1%的普通人群。22q11缺失综合征患者中30%出现精神分裂症,该人群claudin-5基因单倍剂量不足。本研究表明claudin-5基因变异与22q11DS中的精神分裂症弱相关,导致内皮细胞中claudin-5表达减少75%。小鼠脑中靶向AAV介导的claudin-5抑制导致局部BBB破坏和行为改变。诱导性敲低小鼠模型显示claudin-5抑制通过独特行为表型与精神病性症状关联,包括学习记忆损害、焦虑样行为和感觉运动门控异常。这些动物在claudin-5抑制3-4周后出现癫痫并死亡。抗精神病药物在体外和体内剂量依赖性增加claudin-5表达,而精神分裂症患者死后脑中观察到claudin-5异常不连续表达。这些数据提示BBB破坏可能是精神分裂症发展的修饰因素,直接靶向BBB的药物可能提供新治疗机会。

要点

  • Claudin-5基因变异与22q11DS中精神分裂症弱相关,内皮细胞表达减少75%
  • 小鼠claudin-5抑制导致BBB破坏及精神病相关行为表型
  • 抗精神病药物剂量依赖性增加claudin-5表达

核心结论

  • BBB破坏可能是精神分裂症发展的修饰因素。
  • 直接靶向BBB的药物可能提供治疗精神分裂症的新机会。

研究设计与样本

  • 研究包括22q11DS患者遗传关联分析、小鼠AAV介导claudin-5抑制实验、诱导性敲低小鼠模型、体外和体内抗精神病药物实验以及精神分裂症患者死后脑组织观察。

主要发现

  • claudin-5基因变异与22q11DS中的精神分裂症弱相关,导致内皮细胞中claudin-5表达减少75%。
  • 小鼠脑中靶向AAV介导的claudin-5抑制导致局部BBB破坏和行为改变。
  • 诱导性敲低小鼠模型显示claudin-5抑制与精神病性症状关联,表现为学习记忆损害、焦虑样行为和感觉运动门控异常。
  • 这些动物在claudin-5抑制3-4周后出现癫痫并死亡。
  • 抗精神病药物在体外和体内剂量依赖性增加claudin-5表达,精神分裂症患者死后脑中观察到claudin-5异常不连续表达。

关键数值与推荐

  • 精神分裂症影响高达1%的普通人群。
  • 22q11缺失综合征患者中30%出现精神分裂症。
  • claudin-5表达减少75%与22q11DS中精神分裂症相关。
  • claudin-5抑制3-4周后动物出现癫痫并死亡。

临床怎么用

  • Claudin-5和BBB完整性可能作为精神分裂症的潜在生物标志物或治疗靶点。
  • 抗精神病药物可能通过增加claudin-5表达发挥部分治疗作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Schizophrenia is a neurodevelopmental disorder that affects up to 1% of the general population. Various genes show associations with schizophrenia and a very weak nominal association with the tight junction protein, claudin-5, has previously been identified. Claudin-5 is expressed in endothelial cells forming part of the blood-brain barrier (BBB). Furthermore, schizophrenia occurs in 30% of individuals with 22q11 deletion syndrome (22q11DS), a population who are haploinsufficient for the claudin-5 gene. Here, we show that a variant in the claudin-5 gene is weakly associated with schizophrenia in 22q11DS, leading to 75% less claudin-5 being expressed in endothelial cells. We also show that targeted adeno-associated virus-mediated suppression of claudin-5 in the mouse brain results in localized BBB disruption and behavioural changes. Using an inducible 'knockdown' mouse model, we further link claudin-5 suppression with psychosis through a distinct behavioural phenotype showing impairments in learning and memory, anxiety-like behaviour and sensorimotor gating. In addition, these animals develop seizures and die after 3-4 weeks of claudin-5 suppression, reinforcing the crucial role of claudin-5 in normal neurological function. Finally, we show that anti-psychotic medications dose-dependently increase claudin-5 expression in vitro and in vivo while aberrant, discontinuous expression of claudin-5 in the brains of schizophrenic patients post mortem was observed compared to age-matched controls. Together, these data suggest that BBB disruption may be a modifying factor in the development of schizophrenia and that drugs directly targeting the BBB may offer new therapeutic opportunities for treating this disorder.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Greene C, Kealy J, Humphries MM, et al. Dose-dependent expression of claudin-5 is a modifying factor in schizophrenia. Mol Psychiatry. 2017. PMID: 28993710. doi:10.1038/mp.2017.156

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。